Clinical Trial Update: Safety and Efficacy of DNK333 in Atopic Dermatitis Patients [Phase 2]

View source ↗

Summary

Phase 2 trial of DNK333 for safety and efficacy in patients with Atopic Dermatitis has completed. The study targeted pruritus symptoms in this population.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• DNK333

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Pruritus in Patients With Atopic Dermatitis | Phase 2 | Status: COMPLETED